JAK2 V617F Mutation Analysis

Message

Interfaced

Test Code

JAK2B

Quest Code

92473

Alias/See Also

JAK2V617FBM

Preferred Specimen

4 mL whole blood or 3 mL bone marrow aspirate collected in an EDTA (lavender-top) tube

Minimum Volume

3 mL whole blood • 1 mL bone marrow aspirate

Other Acceptable Specimens

Whole blood or bone marrow aspirate collected in: Sodium heparin (green-top) tube • Fixed cell pellet collected in: Plastic leak-proof container • Extracted DNA from CLIA-certified laboratory collected in: Sterile leak-proof container

Transport Container

EDTA (lavender-top) tube

Transport Temperature

Room temperature

Specimen Stability

Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable

Extracted DNA
Room temperature:7 days
Refrigerated: 14 days
Frozen: 1 year

Methodology
Next-Generation Sequencing

FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Setup Schedule

Daily

Reference Range

See Laboratory Report

Clinical Significance

This advanced DNA-based, next-generation sequencing (NGS) assay analyses leukocytes from blood or bone marrow aspirate for mutation at condon 617 of JAK2. The JAK2 V617F mutation is associated with myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Performing Laboratory

Quest Diagnostics Nichols Institute-Chantilly VA

14225 Newbrook Drive

Chantilly, VA 20151-2228

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.